Global CINV Existing and Pipeline Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Publisher Name :
Date: 13-Sep-2018
No. of pages: 116

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).

Scope of the Report:

This report focuses on the CINV Existing and Pipeline Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for CINV Existing and Pipeline Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

-GlaxoSmithKline

-Helsinn

-Heron Therapeutics

-Merck

-Tesaro

Market Segment by Regions, regional analysis covers

-North America (United States, Canada and Mexico)

-Europe (Germany, France, UK, Russia and Italy)

-Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

-South America (Brazil, Argentina, Colombia etc.)

-Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

-Aloxi (palonosetron)

-Zofran Generic (ondansetron)

-Kytril Generic (granisetron)

-Emend (aprepitant)

-Akynzeo (netupitant-palonosetron)

-SUSTOL (extended release granisetron injection)

-Rolapitant

Market Segment by Applications, can be divided into

-Hospitals

-Specialty Clinics

-Diagnostic Centers Therapeutics

-Hospital Pharmacies

-Drugstores

There are 15 Chapters to deeply display the global CINV Existing and Pipeline Drugs market.

Chapter 1, to describe CINV Existing and Pipeline Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of CINV Existing and Pipeline Drugs, with sales, revenue, and price of CINV Existing and Pipeline Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of CINV Existing and Pipeline Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Global CINV Existing and Pipeline Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Table of Contents
1 Market Overview
1.1 CINV Existing and Pipeline Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Aloxi (palonosetron)
1.2.2 Zofran Generic (ondansetron)
1.2.3 Kytril Generic (granisetron)
1.2.4 Emend (aprepitant)
1.2.5 Akynzeo (netupitant-palonosetron)
1.2.6 SUSTOL (extended release granisetron injection)
1.2.7 Rolapitant
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Specialty Clinics
1.3.3 Diagnostic Centers Therapeutics
1.3.4 Hospital Pharmacies
1.3.5 Drugstores
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 Business Overview
2.1.2 CINV Existing and Pipeline Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Helsinn
2.2.1 Business Overview
2.2.2 CINV Existing and Pipeline Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Heron Therapeutics
2.3.1 Business Overview
2.3.2 CINV Existing and Pipeline Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 CINV Existing and Pipeline Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Tesaro
2.5.1 Business Overview
2.5.2 CINV Existing and Pipeline Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global CINV Existing and Pipeline Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global CINV Existing and Pipeline Drugs Market Analysis by Regions
4.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
4.3 Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
4.5 South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
5 North America CINV Existing and Pipeline Drugs by Countries
5.1 North America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
5.3 Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
6 Europe CINV Existing and Pipeline Drugs by Countries
6.1 Europe CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
6.3 UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
6.4 France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
6.5 Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
6.6 Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific CINV Existing and Pipeline Drugs by Countries
7.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
7.3 Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
7.4 Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
7.5 India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
8 South America CINV Existing and Pipeline Drugs by Countries
8.1 South America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa CINV Existing and Pipeline Drugs by Countries
9.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
9.3 UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
10 Global CINV Existing and Pipeline Drugs Market Segment by Type
10.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2013-2018)
10.2 Aloxi (palonosetron) Sales Growth and Price
10.2.1 Global Aloxi (palonosetron) Sales Growth (2013-2018)
10.2.2 Global Aloxi (palonosetron) Price (2013-2018)
10.3 Zofran Generic (ondansetron) Sales Growth and Price
10.3.1 Global Zofran Generic (ondansetron) Sales Growth (2013-2018)
10.3.2 Global Zofran Generic (ondansetron) Price (2013-2018)
10.4 Kytril Generic (granisetron) Sales Growth and Price
10.4.1 Global Kytril Generic (granisetron) Sales Growth (2013-2018)
10.4.2 Global Kytril Generic (granisetron) Price (2013-2018)
10.5 Emend (aprepitant) Sales Growth and Price
10.5.1 Global Emend (aprepitant) Sales Growth (2013-2018)
10.5.2 Global Emend (aprepitant) Price (2013-2018)
10.6 Akynzeo (netupitant-palonosetron) Sales Growth and Price
10.6.1 Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018)
10.6.2 Global Akynzeo (netupitant-palonosetron) Price (2013-2018)
10.7 SUSTOL (extended release granisetron injection) Sales Growth and Price
10.7.1 Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018)
10.7.2 Global SUSTOL (extended release granisetron injection) Price (2013-2018)
10.8 Rolapitant Sales Growth and Price
10.8.1 Global Rolapitant Sales Growth (2013-2018)
10.8.2 Global Rolapitant Price (2013-2018)
11 Global CINV Existing and Pipeline Drugs Market Segment by Application
11.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Specialty Clinics Sales Growth (2013-2018)
11.4 Diagnostic Centers Therapeutics Sales Growth (2013-2018)
11.5 Hospital Pharmacies Sales Growth (2013-2018)
11.6 Drugstores Sales Growth (2013-2018)
12 CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
12.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 CINV Existing and Pipeline Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
12.2.2 Europe CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
12.2.4 South America CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
12.3 CINV Existing and Pipeline Drugs Market Forecast by Type (2018-2023)
12.3.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023)
12.4 CINV Existing and Pipeline Drugs Market Forecast by Application (2018-2023)
12.4.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure CINV Existing and Pipeline Drugs Picture
Table Product Specifications of CINV Existing and Pipeline Drugs
Figure Global Sales Market Share of CINV Existing and Pipeline Drugs by Types in 2017
Table CINV Existing and Pipeline Drugs Types for Major Manufacturers
Figure Aloxi (palonosetron) Picture
Figure Zofran Generic (ondansetron) Picture
Figure Kytril Generic (granisetron) Picture
Figure Emend (aprepitant) Picture
Figure Akynzeo (netupitant-palonosetron) Picture
Figure SUSTOL (extended release granisetron injection) Picture
Figure Rolapitant Picture
Figure CINV Existing and Pipeline Drugs Sales Market Share by Applications in 2017
Figure Hospitals Picture
Figure Specialty Clinics Picture
Figure Diagnostic Centers Therapeutics Picture
Figure Hospital Pharmacies Picture
Figure Drugstores Picture
Figure United States CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Canada CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Germany CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure France CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure UK CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Russia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Italy CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure China CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Japan CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Korea CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure India CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)
Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table GlaxoSmithKline CINV Existing and Pipeline Drugs Type and Applications
Table GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Helsinn Basic Information, Manufacturing Base and Competitors
Table Helsinn CINV Existing and Pipeline Drugs Type and Applications
Table Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Heron Therapeutics Basic Information, Manufacturing Base and Competitors
Table Heron Therapeutics CINV Existing and Pipeline Drugs Type and Applications
Table Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Merck Basic Information, Manufacturing Base and Competitors
Table Merck CINV Existing and Pipeline Drugs Type and Applications
Table Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Tesaro Basic Information, Manufacturing Base and Competitors
Table Tesaro CINV Existing and Pipeline Drugs Type and Applications
Table Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Global CINV Existing and Pipeline Drugs Sales by Manufacturer (2016-2017)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2016
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2017
Table Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2016-2017)
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2016
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2017
Figure Top 3 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017
Figure Top 6 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017
Figure Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)
Table Global CINV Existing and Pipeline Drugs Sales by Regions (2013-2018)
Table Global CINV Existing and Pipeline Drugs Sales Market Share by Regions (2013-2018)
Table Global CINV Existing and Pipeline Drugs Revenue by Regions (2013-2018)
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2013
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2017
Figure North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure North America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)
Table North America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)
Table North America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)
Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2013
Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017
Table North America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)
Table North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)
Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013
Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017
Figure United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Europe CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)
Table Europe CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)
Table Europe CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)
Table Europe CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)
Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2016
Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017
Figure Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)
Table Asia-Pacific CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)
Table Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries 2017
Table Asia-Pacific CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)
Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Countries 2017
Figure China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure South America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)
Table South America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)
Table South America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)
Figure South America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017
Table South America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)
Table South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)
Figure South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017
Figure Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)
Table Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017
Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)
Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013
Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017
Figure Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Figure South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)
Table Global CINV Existing and Pipeline Drugs Sales by Type (2013-2018)
Table Global CINV Existing and Pipeline Drugs Sales Share by Type (2013-2018)
Table Global CINV Existing and Pipeline Drugs Revenue by Type (2013-2018)
Table Global CINV Existing and Pipeline Drugs Revenue Share by Type (2013-2018)
Figure Global Aloxi (palonosetron) Sales Growth (2013-2018)
Figure Global Aloxi (palonosetron) Price (2013-2018)
Figure Global Zofran Generic (ondansetron) Sales Growth (2013-2018)
Figure Global Zofran Generic (ondansetron) Price (2013-2018)
Figure Global Kytril Generic (granisetron) Sales Growth (2013-2018)
Figure Global Kytril Generic (granisetron) Price (2013-2018)
Figure Global Emend (aprepitant) Sales Growth (2013-2018)
Figure Global Emend (aprepitant) Price (2013-2018)
Figure Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018)
Figure Global Akynzeo (netupitant-palonosetron) Price (2013-2018)
Figure Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018)
Figure Global SUSTOL (extended release granisetron injection) Price (2013-2018)
Figure Global Rolapitant Sales Growth (2013-2018)
Figure Global Rolapitant Price (2013-2018)
Table Global CINV Existing and Pipeline Drugs Sales by Application (2013-2018)
Table Global CINV Existing and Pipeline Drugs Sales Share by Application (2013-2018)
Figure Global Specialty Clinics Sales Growth (2013-2018)
Figure Global Diagnostic Centers Therapeutics Sales Growth (2013-2018)
Figure Global Hospital Pharmacies Sales Growth (2013-2018)
Figure Global Drugstores Sales Growth (2013-2018)
Figure Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023)
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Regions (2018-2023)
Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Regions (2018-2023)
Figure North America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
Figure Europe Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
Figure Asia-Pacific Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
Figure South America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
Figure Middle East and Africa Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023)
Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023)
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023)
Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List
  • Global White Willow Bark Extract Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 117
    White willow bark is used for the treatment of pain such as lower back and osteoarthritis in regions of Asia and Europe. Scope of the Report: White willow bark extract is slowly gaining popularity and is expected to show a steady increase in the revenue growth. The worldwide market for White Willow Bark Extract is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR ......
  • Global Wintergreen Oil Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Wintergreen oil is of high importance and has a high reputation since ages as it possesses various therapeutic properties such as anti-rheumatic, anti-arthritic, antiseptic, aromatic, analgesic properties, etc. Scope of the Report: Due to change in the market trend, people are more interested in natural products which will play an important role in fueling the growth of present Wintergreen Oil Market. The worldwide market for Wintergreen Oil is expected to grow at a ......
  • Global Irritable Bowel Syndrome Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 115
    Irritable bowel syndrome is a functional gastrointestinal disorder of gut that may be characterized by colon muscle contractions. Irritable bowel syndrome is a common disorder. There is no complete cure for the irritable bowel syndrome. Medicines used in irritable bowel syndrome are effective in decreasing the symptoms. Scope of the Report: Increased awareness about available treatment among the patients, medical community is one of the major driver in global irritable bowe......
  • Global Peppermint Oil Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 120
    Peppermint Oil is the oil that is extracted from the stem and flowers of the peppermint herb. Scope of the Report: This report focuses on the Peppermint Oil in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for Peppermint Oil is expected to grow at a CAGR of roughly xx% over the next five years, wi......
  • Global Dermal Adhesives Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 120
    A dermal adhesive (or skin glue) is a glue used to close wounds in the skin, as an alternative to sutures, staples or clips. Scope of the Report: Glued closure produces less scarring and is less prone to infection than sutured or stapled closure. There is also no residual closure to remove, so follow-up visits for removal are not required. The factor that contributes to the growth of the global Skin Glue market is the rising number of traumatic injuries. The market g......
  • Global Skin Glue Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 123
    A dermal adhesive (or skin glue) is a glue used to close wounds in the skin, as an alternative to sutures, staples or clips. Scope of the Report: Glued closure produces less scarring and is less prone to infection than sutured or stapled closure. There is also no residual closure to remove, so follow-up visits for removal are not required. The factor that contributes to the growth of the global Skin Glue market is the rising number of traumatic injuries. The market g......
  • Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 124
    Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help......
  • Global Alpha Glucosidase Inhibitors Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 124
    Alpha-glucosidase is an enzyme that is inhibited by alpha-glucosidase inhibitor drugs. Alpha-glucosidase helps in absorption of carbohydrates by breaking down carbohydrates into tiny sugar molecules such as glucose. The inhibition is reversible, and competitive inhibition. Alpha-glucosidase inhibitor drugs help in delaying glucose absorption and slow the digestion of carbohydrates. This results in lower rise of glucose in the blood after meals and remains effective throughout the day. ......
  • Global Cancer Pain Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 120
    Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response. Scope of the Report: The report, states that opioids will continue to dominate as a breakthrough cancer pain treatment, mostly due to available generics and physician familiarity. The worldwide market for Cancer Pain is expected to grow at a CAGR of roughly xx......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs